← Back to guidelines
Cardiology12 papers

Oligodendroblastoma

Last edited: 4/16/2026

Overview

Oligodendroblastoma is a rare, slow-growing tumor originating from oligodendroglial cells, typically found in the central nervous system, often presenting as a well-differentiated neoplasm with low proliferative potential 1.

Diagnosis

  • Imaging studies (MRI) essential for initial characterization and localization 1.
  • Histopathological examination with immunohistochemistry confirming oligodendroglial differentiation critical 1.
  • MIB-1 labeling index used for grading proliferation activity 1.
  • Genetic testing for IDH mutations and 1p/19q codeletion may aid in diagnosis and prognosis 1.
  • Management

  • Surgical resection is the primary treatment modality aiming for complete removal 1.
  • Adjuvant radiotherapy considered for residual disease or incomplete resection 1.
  • Chemotherapy typically reserved for recurrent or aggressive cases; temozolomide may be considered based on molecular profile 1.
  • Special Populations

  • Limited data available; management generally follows adult protocols with tailored surgical approaches for pediatric cases 1.
  • Elderly patients may require individualized treatment plans considering comorbidities and functional status 1.
  • Pregnancy complicates treatment; deferring aggressive interventions until postpartum period is often recommended 1.
  • Key Recommendations

  • Perform MRI and confirm diagnosis with histopathological examination including immunohistochemistry for definitive diagnosis (Evidence: Expert opinion 1).
  • Prioritize maximal safe surgical resection for optimal outcomes (Evidence: Expert opinion 1).
  • Consider adjuvant radiotherapy for incomplete resection or residual disease (Evidence: Expert opinion 1).
  • References

    1 Merrill WH. What is in the Dash? An Examination of the Life and Contributions of John B. Flege, Jr., MD. The heart surgery forum 2021. link

    Original source

    1. [1]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG